3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
2
Lymphoid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
38
Leukemia
19
Burkitt Lymphoma
13
Lymphoma
9
Leukemia, Biphenotypic, Acute
7
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
6
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
3
Recurrence
2
Neoplasm, Residual
2
Down Syndrome
2
Dendritic Cell Sarcoma, Interdigitating
2
Thrombocytopenia
1
Neutropenia
1
Neoplasms
1
Lymphoma, T-Cell
1
Lymphoma, Non-Hodgkin
1
Hodgkin Disease
1
Interventions
Cyclophosphamide
35
Rituximab
33
venetoclax
24
ibrutinib
14
Vincristine
14
Prednisone
14
Doxorubicin
14
Gemcitabine
13
pembrolizumab
12
fludarabine
12
Bendamustine Hydrochloride
11
Etoposide
10
obinutuzumab
9
Filgrastim
9
Dexamethasone
9
Bortezomib
9
fludarabine phosphate
8
Mycophenolic Acid
8
Drug Therapy
8
ofatumumab
7
Whole-Body Irradiation
7
Sirolimus
7
Peripheral Blood Stem Cell Transplantation
7
Methotrexate
7
Busulfan
7
Therapeutics
6
Radiotherapy
6
Mesna
6
Lenalidomide
6
Ipilimumab
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms
×
Thioguanine
×
Lymphoid
×
Clear all
NCT02912676
2020-04-15
TEAM
Rigshospitalet, Denmark
Phase 1/2
Completed
30 enrolled